Yubo International Biotech Ltd (YBGJ) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN US9883661004
Yubo International Biotech Ltd financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 12,353.00 USD |
| Gross profit | 8,165.00 USD |
| Operating income | -1.19 m USD |
| EBIT | -1.19 m USD |
| Net income | -1.08 m USD |
| Diluted EPS – continuing operations | -0.01 USD |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yubo International Biotech Ltd
Yubo International Biotech Limited, through its subsidiaries, focuses on the research, development, and application of endometrial stem cells. The company offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. It also provides light application products, including respiratory atomization products; cell basidiomycetes compound drink/beverage; and facial care, eye care, and hair care series products. Yubo International Biotech Limited is headquartered in Beijing, China.
More stocks
- My Size, Inc. (MYSZ)
- Evofem Biosciences, Inc. (EVFM)
- Nu-Med Plus, Inc. (NUMD)
- GENERATION INCOME PROPERTIES, INC. (GIPR)
- Sky Century Investment, Inc. (SKYI)
- Dream Homes & Development Corp. (DREM)
- iPower Inc. (IPW)
- Naploy Corp. (NPLY)
- WYTEC INTERNATIONAL INC (WYTC)
- Authentic Holdings, Inc. (AHRO)
- Hi-Great Group Holding Co (HIGR)
- Rapid Line Inc. (RPDL)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.